Immunophenotyping of Peripheral Blood in NSCLC Patients Discriminates Responders to Immune Checkpoint Inhibitors

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 Feb 22

PMID 38383923

Authors

Ludmila Krizova

Iva Benesova

Petra Zemanova

Jan Spacek

Zuzana Strizova

Zuzana Humlova

Veronika Mikulova

Lubos Petruzelka

Michal Vocka

Affiliations

Soon will be listed here.

Abstract

Purpose: Immune checkpoint inhibitors (ICIs) dramatically changed the prognosis of patients with NSCLC. Unfortunately, a reliable predictive biomarker is still missing. Commonly used biomarkers, such as PD-L1, MSI, or TMB, are not quite accurate in predicting ICI efficacy.

Methods: In this prospective observational cohort study, we investigated the predictive role of erythrocytes, thrombocytes, innate and adaptive immune cells, complement proteins (C3, C4), and cytokines from peripheral blood of 224 patients with stage III/IV NSCLC treated with ICI alone (pembrolizumab, nivolumab, and atezolizumab) or in combination (nivolumab + ipilimumab) with chemotherapy. These values were analyzed for associations with the response to the treatment and survival endpoints.

Results: Higher baseline Tregs, MPV, hemoglobin, and lower monocyte levels were associated with favorable PFS and OS. Moreover, increased baseline basophils and lower levels of C3 predicted significantly improved PFS. The levels of the baseline immature granulocytes, C3, and monocytes were significantly associated with the occurrence of partial regression at the first restaging. Multiple studied parameters (n = 9) were related to PFS benefit at the time of first restaging as compared to baseline values. In addition, PFS nonbenefit group showed a decrease in lymphocyte count after three months of therapy. The OS benefit was associated with higher levels of lymphocytes, erythrocytes, hemoglobin, MCV, and MPV, and a lower value of NLR after three months of treatment.

Conclusion: Our work suggests that parameters from peripheral venous blood may be potential biomarkers in NSCLC patients on ICI. The baseline values of Tregs, C3, monocytes, and MPV are especially recommended for further investigation.

Citing Articles

The latest advances in liquid biopsy for lung cancer-a narrative review.

She W, Garitaonaindia Y, Lin Y Transl Lung Cancer Res. 2024; 13(11):3241-3251.

PMID: 39669995 PMC: 11632431. DOI: 10.21037/tlcr-24-828.

References

Kargl J, Busch S, Yang G, Kim K, Hanke M, Metz H . Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017; 8:14381. PMC: 5296654. DOI: 10.1038/ncomms14381. View

Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilanci K . Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2016; 12(3):922-929. DOI: 10.1111/crj.12605. View

Principe D, Chiec L, Mohindra N, Munshi H . Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Front Oncol. 2021; 11:684098. PMC: 8204014. DOI: 10.3389/fonc.2021.684098. View

Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y . The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020; 21(11):1346-1358. DOI: 10.1038/s41590-020-0769-3. View

Kim S, Sumner W, Miyauchi S, Cohen E, Califano J, Sharabi A . Role of B Cells in Responses to Checkpoint Blockade Immunotherapy and Overall Survival of Cancer Patients. Clin Cancer Res. 2021; 27(22):6075-6082. PMC: 8976464. DOI: 10.1158/1078-0432.CCR-21-0697. View

Wu C, Qiu Y, Zhang R, Li X, Liang H, Wang M . Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer. J Transl Med. 2022; 20(1):386. PMC: 9441040. DOI: 10.1186/s12967-022-03598-y. View

Chocarro L, Blanco E, Zuazo M, Arasanz H, Bocanegra A, Fernandez-Rubio L . Understanding LAG-3 Signaling. Int J Mol Sci. 2021; 22(10). PMC: 8156499. DOI: 10.3390/ijms22105282. View

Bagley S, Kothari S, Aggarwal C, Bauml J, Alley E, Evans T . Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017; 106:1-7. DOI: 10.1016/j.lungcan.2017.01.013. View

Luchini C, Bibeau F, Ligtenberg M, Singh N, Nottegar A, Bosse T . ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019; 30(8):1232-1243. DOI: 10.1093/annonc/mdz116. View

10.

Mareckova H, Ravdan A, Fucikova T, Janatkova I . [Detection of the production of intracellular cytokines by T lymphocytes using flow cytometry--methodologic problems]. Epidemiol Mikrobiol Imunol. 2002; 51(3):111-8. View

11.

Koh J, Hur J, Lee K, Kim M, Heo J, Ku B . Regulatory (FoxP3) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. 2020; 10(1):18994. PMC: 7642363. DOI: 10.1038/s41598-020-76130-1. View

12.

Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

13.

Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G . Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol. 2020; 10:654. PMC: 7324627. DOI: 10.3389/fonc.2020.00654. View

14.

An H, Chon H, Kim C . Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. Int J Mol Sci. 2021; 22(17). PMC: 8430528. DOI: 10.3390/ijms22179414. View

15.

Scheel A, Ansen S, Schultheis A, Scheffler M, Fischer R, Michels S . PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. Oncoimmunology. 2016; 5(5):e1131379. PMC: 4910698. DOI: 10.1080/2162402X.2015.1131379. View

16.

McGrail D, Pilie P, Rashid N, Voorwerk L, Slagter M, Kok M . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5):661-672. PMC: 8053682. DOI: 10.1016/j.annonc.2021.02.006. View

17.

Patel A, Richter A, Drayson M, Middleton G . The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer. Cancer Immunol Immunother. 2020; 69(3):325-342. PMC: 7044257. DOI: 10.1007/s00262-019-02461-2. View

18.

Caliman E, Fancelli S, Ottanelli C, Mazzoni F, Paglialunga L, Lavacchi D . Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treat Res Commun. 2022; 32:100603. DOI: 10.1016/j.ctarc.2022.100603. View

19.

Ayers K, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K . A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer. 2021; 21(1):441. PMC: 8059160. DOI: 10.1186/s12885-021-08194-9. View

20.

Wei S, Duffy C, Allison J . Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018; 8(9):1069-1086. DOI: 10.1158/2159-8290.CD-18-0367. View